DOCSLIB.ORG

(A) TCGA-LUAD, (B) TCGA-LUSC, (C) Database from Rizvi H, Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(A) TCGA-LUAD, (B) TCGA-LUSC, (C) Database from Rizvi H, Et Al Figure S1. The correlations of TMB value between panel sequencing and WES in published databases. (A) TCGA-LUAD, (B) TCGA-LUSC, (C) Database from Rizvi H, et al. J Clin Oncol, 2018;36. Abbreviations: TMB, tumor mutational burden; TCGA, The Cancer Genome Atlas; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; WES, wholeexome sequencing A B C 1 / 3 Figure S2. The comparison of multi-region tTMB among different NSCLC subtypes. Abbreviations: TMB, tumor mutational burden; tTMB, tissue TMB 2 / 3 Figure S3. The comparisons and overlaps of tumor-derived mutational profiles among tumor tissues in each region and the corresponding ctDNA. The P0XX was the patient No. shown at the top. Each tumor region (T1, T2, T3…) with plasma (P) were arranged in the x axis. ctDNA was isolated from plasma (more details in Supplementary Methods). Right y axis displayed tumor-derived mutational profiles in detail. The detected mutations were shown in red, while undetected cases were shown in gray. 3 / 3 P001 P004 P005 P006 P007 P009 P015 P018 KRAS.p.G12C ATG9B.p.R298C MORC1.p.G97V MLH1.p.L658V EGFR.p.L747_E749del SPTA1.p.S444C VAV1.p.R548W TP53.p.Y163C BAX.p.E41G CSMD3.p.H1455Y FAT1.p.R4481L CHI3L1.p.G37S DDR2.p.R478C APC.p.E2184K EPOR.p.R45P PTCH2.p.E854K TENM3.p.S44I EGFR.p.L858R U2AF1.p.S34F STK11.p.I238F MAEL.c.703.1G.C PIK3CA.p.R108H MSH6.p.S1340C EGFR.p.E746_A750del TSC1.p.R779. FLT1.p.K37E XRCC1.p.E455Q TP53.c.443.2A.C EGFR.p.A750P PPEF1.p.R348Q NTRK3.p.D208E TP53.p.Q105_S110delinsP DNMT3A.p.F563I NF1.p.A1228T CDK13.p.K852Nfs.23 POLR3B.c.1102.3_1102.2delTA COL6A6.p.P1542S MYD88.p.L265P FLT4.p.A601V TERT.c..58.u3403C.A ACIN1.p.K1047N ERBB2.p.G746delinsVC PRKCD.p.G210V EPHA3.p.T519M NOTCH1.p.Q2361. ANKRD27.p.G744V EGFR.p.L858R FAT1.p.V4575E PRSS1.p.E32D RB1.p.A433Lfs.24 ARHGEF1.p.S25F TP53.p.V134A TP53.p.H193Y EZH2.p.S40Ifs.17 KDR.p.S410R P P T1 T2 T3 INHBA.p.E154K EGFR.gain T1 T2 T3 T4 OR5L2.p.C260. NTRK2.p.R413I ERBB4.p.R484K P T1 T2 T3 T4 T5 T6 P P019 P026 EPHA5.p.F214C MLL3.p.Q560Sfs.53 T1 T2 T3 T4 KDR.gain TP53.p.M345Nfs.39 LCT.p.F314Lfs.7 MTTP.p.S383I EPHA5.p.S992I MSH3.p.A51.12.9. KIT.gain PDGFRA.gain TP53.p.R234L P003 MAP2K1.p.L375P P POM121L12.p.D11E BRAF.c.2128.2_2128delAGA T1 T2 T3 P002 P FMN2.p.E1640K T1 T2 T3 T4 CTNNB1.p.S37F CCNE1.gain KEAP1.p.E244K TP53.p.W52. ATR.p.Q416E EGFR p.E746_A750del EGFR.p.E746_A750del MLL4.p.D1842E P EGFR.p.L858R P T1 T2 T3 T4 T1 T2 T3 T4 CTNNB1.p.Q72E P T1 T2 T3 T4 T5 T6 T7 NOTCH2.p.E301K ALK.p.P496S P T1 T2 T3 T4 T5 T6 P RB1.c.1696.1G.C T1 T2 T3 T4 T5 P T1 T2 T3 T4 T5 T6 T7 T8 P008 P016 P017 P020 P021 P030 P025 FBXW7.p.R473G TRIM58.p.D321E GNAS.p.S110C MTOR.p.F191Lfs.20 SLC25A30.p.W266Gfs.5 OR4A15.p.V222I MTOR.p.N1264S NAV3.p.D414V CNTNAP5.p.Q909L AR.p.Q71R SMARCA4.p.E665_E666delinsD. MET.p.Y989N IGSF9.c.1198.1G.A BRAF.p.G469V ROS1.p.L567M DOCK3.p.L1854H MYD88.p.L265P AURKA.p.K143E SEPT12.p.R266Q FAM5C.p.P690T NOTCH2.p.R1578C ABCC11.p.C609F MTOR.p.N2494Ifs.74 TP53.p.K100N NOTCH2.p.L1844V ROS1.p.R2039P FGFR1.p.R448W MYC.p.K158E KRAS.p.G12V PTPRD.p.T799A NF1.p.V350G GNAQ.c.736.2_736.1insA OR4A15.p.L83M CDH18.p.G664. MLL.p.P36L C1S.p.N233Tfs.6 STK11.c.456_464.6del CNTN5.p.T176N MET.c.2941.1G.T MLH1.p.Q149Rfs.11 RET.p.G727. CRYBG3.p.K2356Rfs.3 MLL4.p.C1325F TMEM247.p.Q152_Q153ins ERBB4.p.P309Lfs.7 KRAS.p.G12D FGFR4.p.R196L TNN.p.P680Q TP53.p.H76Ifs.8 AR.p.I304V FAT1.p.D1204V ABL1.p.T993A NAV3.p.A503P EGFR.p.L858R FLT3.p.Y874C CDH23.p.I743F GNAS.p.R524S FBXW7.p.W486Gfs.12 SMARCA4.p.A503S CCNE1.p.R385M PDGFRB.p.P725R PTPRD.p.D848N RICTOR.p.I188F CDK13.p.R1317Efs.39 ALK.p.A195V RET.p.E713D SLCO5A1.p.V677L TSC1.c.2623.2_2623.1insA MED12.p.Q2146.5.4. ROS1.p.G666Vfs.16 CD274.p.L214. ALK.p.M1478T AR.p.G260V MLL3.p.A221P EML4.ALK FOXL2.p.P285Rfs.71 TP53.p.R209L ROS1.p.V1175L EPHA5.p.I850T COL25A1.p.G382Dfs.48 TP53.p.N272Kfs.33 TP53.p.R119L OR4C6.p.M279I DNMT3A.p.G332R FGFR3.p.Y673Hfs.5 CTNNA2.p.R125Q MTOR.p.E742K POM121L12.p.R49P GNAS.p.S455Y OR4C6.p.L280V GPR114.p.M34T ERBB4.p.G1293V EGFR.gain TP53.p.R234S GAB2.p.Q562Sfs.172 OR4A15.p.P86H FAT1.p.P381R MLH1.p.G517R NOTCH1.p.E1583Sfs.33 OR2T4.p.I229F EPHA5.p.P561L GFRAL.p.H206Q MITF.p.A285Pfs.12 CDK4.gain EPHA5.p.D180Y PTPRD.p.V834L MLL4.p.V169L P P P T1 T2 T3 T4 OR6F1.p.D269Y THBS2.p.C835Y T5 T6 T7 T2 T3 T4 T5 T6 T1 T1 T2 T3 T4 T5 CRKL.p.P231S EZH2.p.T244M P ANKRD36B.p.I480M T1 T2 T3 T4 T5 T6 T7 T8 AR.p.Q74R FAT1.c.3629_3642.5del SMARCA4.p.Q459_K461del TERT.c..58.u2712G.T P T1 T2 T3 T4 T5 T6 FGFR2.p.C809F P ERBB2.p.E580G T1 T2 T3 T4 T5 T6 T7 T8 AXL.p.E281G TP53.p.S201C P T2 T5 T1 T6 T3 T4 P022 P027 P028 P029 P033 P034 P037 MED12.p.S2163F HDAC4.p.K1071N MLL4.p.D131H ROS1.p.S852R APC.p.Q1469. NOTCH4.p.G1081C EMID2.p.L96Q EPHA2.p.V442A GNAQ.p.G46W CCND2.p.L20M SMO.p.E779K TP53.p.C199F TSC1.p.A566V MED12.p.G1293A COL6A5.p.M1319V NOTCH2.p.P2463S HGF.p.F99L NOTCH2.p.G523V ENPP2.p.R446. OR2T4.p.A30D PTPRD.p.D991H ATM.p.A2346G EGFR.p.E45K TRPC5.p.M86I CTNNB1.p.I507. TMEM247.p.G86. HDAC4.p.E645D NF1.p.Q83. MLL3.p.H4429L NOTCH4.c.2022.1G.T AXL.p.V406L CCND3.p.A266V MTTP.p.S385C BRD2.p.K127N BRCA1.p.K1233. NF1.p.I177T CDH23.p.G252C ROCK1.p.V1127G ESR1.p.D332Y MITF.p.Q30. TERT.c..58.u1680C.A SMARCA4.p.K455M GPATCH2.p.P383L HECTD4.p.G4219V C11orf30.p.Q728. TP53.p.A99V TMTC4.c.1586.1G.A FUNDC1.p.E130Q PDGFRA.p.P698Q FGFR4.p.V740L CNOT3.p.K544N FAT1.p.P1877Lfs.20 RICTOR.p.A3V KIAA0319.p.D909Y GNAS.p.S532C DNMT3A.p.G298W NF1.p.A2028S FGFR3.p.S612F CSMD3.p.H775N MLL3.p.D3152N CCNE1.p.R27H SETD2.p.D631N FAM5C.p.Q471K MPL.p.R43. PIK3R2.p.G363C MAP3K1.p.K953R TESC.p.R59L SETD2.p.E850K GATA3.c.1050.2T.A CHEK2.p.L106V EPHA3.c.1307.1G.T FASTK.p.K530N EPHA2.p.N71Y NTRK3.p.C166F PALB2.p.S631P DDR2.p.R746L MAP3K1.p.P981S MLL4.p.P1124R CD97.p.K156Rfs.6 TP53.p.G227. EPOR.p.S176F EPHA3.p.P291Q NF2.c.1575.1G.C OR4A15.p.C217F XRCC1.p.I232M MLL3.p.G3106R CNOT3.p.P269Afs.15 SMARCA4.p.Y439. VEGFA.p.G117V FGFR1.p.F114V KRAS.p.G12V HDAC4.p.S735R TGFBR1.p.G301R KEAP1.p.D526Y MDM4.p.R149G HCN1.p.R593Q KEAP1.p.R601L SMARCA4.p.E1242G RB1.p.T601Ifs.7 TP53.p.R234H FAT1.p.V2936. MLL4.p.D168H NOTCH4.p.P445H TP53.p.R209L HCLS1.p.E394D FBXW7.p.W244. RPS6KB1.p.A348T BRCA2.p.E2599K KRAS.p.G12V ERBB2.p.R816L PTEN.p.V166G FGFR3.p.S249F ERBB4.p.P572L ERBB2.c.2086.1G.A CDH23.p.F895L MLL3.p.Q1211. CDK12.p.S256W OR2T4.p.Y136. ABL2.p.E398K ARHGAP40.p.P447T NF1.p.L1183V FAT1.p.A3666T FLT1.p.S530P NOTCH2.p.H2041R KEAP1.p.A40S DUOX1.p.R1219Q MLL3.p.S1228. DDR2.p.R128H MAP2K1.p.R201C NOTCH1.p.R2327W TP53.p.C203F RB1.p.Q257. STAT3.p.E625D P WAS.c.1453.1G.T ERBB4.p.G565C T1 T2 T3 T4 T5 T6 T7 T8 ELAVL3.p.A18Rfs.34 HDAC1.p.G280A OR2T4.p.L58I NOTCH2.p.E494Q ROBO3.p.S307I OR4C6.p.C205F C1S.p.Q318H FGFR1.p.E803. ABCC11.p.E1169K ERBB3.p.Q239E TCP11.p.Q43H DDR2.p.P384H P OR6F1.p.T160I EPHA3.p.Q139. CCND1.gain T1 T2 T3 T4 T5 T6 ABCC11.p.L958Q ATM.p.R250Q CCND1.p.E76Q ALK.p.E152. KCNH6.p.D673H DNMT3A.p.G800R RB1.p.T601Ifs.7.1 HRAS.c..53.1G.T BRCA2.p.D1990H P MCL1.p.G59_G62del OR5L2.p.L220. MLL3.p.R4478P T1 T2 T3 T4 T5 T6 T7 T8 FAT1.p.M1533I ALK.p.E717K NOTCH2.p.E2143Q CDKN2A.p.G101V PRKAA1.p.S5R MLL.p.D649H SETD2.p.R484S P FGFR2.p.C740G OR5L2.p.T57N RAF1.p.E503Q T1 T2 T3 T4 CDK12.gain HGF.p.V64. CDH23.c.754.2A.T EPHA3.p.R330K ERBB2.gain FOXL2.p.Q344. CDK13.p.S1066. EGFR.p.Y1110C NF1.p.D1849N P T1 T3 T4 T5 T6 PDGFRA.p.P6S T2 T7 T8 KDR.p.Q72. CD74.ROS1 P030 P031 P035 P036 TP53.p.Q38.
Load more

Recommended publications
  • Journal of Pediatric Gastroenterology and Nutrition, Publish Ahead of Print
    Journal of Pediatric Gastroenterology and Nutrition, Publish Ahead of Print DOI : 10.1097/MPG.0000000000002462 Serologic, but not genetic, markers are associated with impaired anthropometrics at diagnosis of pediatric Crohn’s disease Authors: Sara K. Naramore, MD1, William E. Bennett, Jr., MD, MS1,2, Guanglong Jiang, MS3,4, Subra Kugathasan, MD5, Lee A. Denson, MD6, Jeffrey S. Hyams, MD7, Steven J. Steiner, MD1, and PRO-KIIDS Research Group8† 1Department of Pediatrics, Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Indiana University School of Medicine, Indianapolis, IN 2Department of Pediatrics, Division of Pediatric and Adolescent Comparative Effectiveness Research, Indiana University School of Medicine, Indianapolis, IN 3Department of Medical & Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 4Department of BioHealth Informatics, Indiana University-Purdue University−Indianapolis, Indianapolis, IN 5Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 6Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 7Department of Pediatrics, Connecticut Children’s Medical Center, Hartford, CT 8PRO-KIIDS Research Group, New York, NY †Membership of the PRO-KIIDS Research Group is listed in the Acknowledgements. Principal Investigator and Corresponding Author: Sara Naramore, MD Department of Pediatrics Indiana University School of Medicine Riley Hospital for Children ____________________________________________________ This is the author's manuscript of the article published in final edited form as: Naramore, S. K., Bennett, W. E. J., Jiang, G., Kugathasan, S., Denson, L. A., Hyams, J. S., … Group, and P.-K. R. (2019). Serologic, but not Genetic, Markers are Associated with Impaired Anthropometrics at Diagnosis of Pediatric Crohn’s Disease. Journal of Pediatric Gastroenterology and Nutrition, Publish Ahead of Print.
    [Show full text]
  • Single Cell Derived Clonal Analysis of Human Glioblastoma Links
    SUPPLEMENTARY INFORMATION: Single cell derived clonal analysis of human glioblastoma links functional and genomic heterogeneity ! Mona Meyer*, Jüri Reimand*, Xiaoyang Lan, Renee Head, Xueming Zhu, Michelle Kushida, Jane Bayani, Jessica C. Pressey, Anath Lionel, Ian D. Clarke, Michael Cusimano, Jeremy Squire, Stephen Scherer, Mark Bernstein, Melanie A. Woodin, Gary D. Bader**, and Peter B. Dirks**! ! * These authors contributed equally to this work.! ** Correspondence: [email protected] or [email protected]! ! Supplementary information - Meyer, Reimand et al. Supplementary methods" 4" Patient samples and fluorescence activated cell sorting (FACS)! 4! Differentiation! 4! Immunocytochemistry and EdU Imaging! 4! Proliferation! 5! Western blotting ! 5! Temozolomide treatment! 5! NCI drug library screen! 6! Orthotopic injections! 6! Immunohistochemistry on tumor sections! 6! Promoter methylation of MGMT! 6! Fluorescence in situ Hybridization (FISH)! 7! SNP6 microarray analysis and genome segmentation! 7! Calling copy number alterations! 8! Mapping altered genome segments to genes! 8! Recurrently altered genes with clonal variability! 9! Global analyses of copy number alterations! 9! Phylogenetic analysis of copy number alterations! 10! Microarray analysis! 10! Gene expression differences of TMZ resistant and sensitive clones of GBM-482! 10! Reverse transcription-PCR analyses! 11! Tumor subtype analysis of TMZ-sensitive and resistant clones! 11! Pathway analysis of gene expression in the TMZ-sensitive clone of GBM-482! 11! Supplementary figures and tables" 13" "2 Supplementary information - Meyer, Reimand et al. Table S1: Individual clones from all patient tumors are tumorigenic. ! 14! Fig. S1: clonal tumorigenicity.! 15! Fig. S2: clonal heterogeneity of EGFR and PTEN expression.! 20! Fig. S3: clonal heterogeneity of proliferation.! 21! Fig.
    [Show full text]
  • Sean Raspet – Molecules
    1. Commercial name: Fructaplex© IUPAC Name: 2-(3,3-dimethylcyclohexyl)-2,5,5-trimethyl-1,3-dioxane SMILES: CC1(C)CCCC(C1)C2(C)OCC(C)(C)CO2 Molecular weight: 240.39 g/mol Volume (cubic Angstroems): 258.88 Atoms number (non-hydrogen): 17 miLogP: 4.43 Structure: Biological Properties: Predicted Druglikenessi: GPCR ligand -0.23 Ion channel modulator -0.03 Kinase inhibitor -0.6 Nuclear receptor ligand 0.15 Protease inhibitor -0.28 Enzyme inhibitor 0.15 Commercial name: Fructaplex© IUPAC Name: 2-(3,3-dimethylcyclohexyl)-2,5,5-trimethyl-1,3-dioxane SMILES: CC1(C)CCCC(C1)C2(C)OCC(C)(C)CO2 Predicted Olfactory Receptor Activityii: OR2L13 83.715% OR1G1 82.761% OR10J5 80.569% OR2W1 78.180% OR7A2 77.696% 2. Commercial name: Sylvoxime© IUPAC Name: N-[4-(1-ethoxyethenyl)-3,3,5,5tetramethylcyclohexylidene]hydroxylamine SMILES: CCOC(=C)C1C(C)(C)CC(CC1(C)C)=NO Molecular weight: 239.36 Volume (cubic Angstroems): 252.83 Atoms number (non-hydrogen): 17 miLogP: 4.33 Structure: Biological Properties: Predicted Druglikeness: GPCR ligand -0.6 Ion channel modulator -0.41 Kinase inhibitor -0.93 Nuclear receptor ligand -0.17 Protease inhibitor -0.39 Enzyme inhibitor 0.01 Commercial name: Sylvoxime© IUPAC Name: N-[4-(1-ethoxyethenyl)-3,3,5,5tetramethylcyclohexylidene]hydroxylamine SMILES: CCOC(=C)C1C(C)(C)CC(CC1(C)C)=NO Predicted Olfactory Receptor Activity: OR52D1 71.900% OR1G1 70.394% 0R52I2 70.392% OR52I1 70.390% OR2Y1 70.378% 3. Commercial name: Hyperflor© IUPAC Name: 2-benzyl-1,3-dioxan-5-one SMILES: O=C1COC(CC2=CC=CC=C2)OC1 Molecular weight: 192.21 g/mol Volume
    [Show full text]
  • HOPS-Dependent Endosomal Fusion Required for Efficient Cytosolic Delivery of Therapeutic Peptides and Small Proteins
    HOPS-dependent endosomal fusion required for efficient cytosolic delivery of therapeutic peptides and small proteins Angela Steinauera, Jonathan R. LaRochelleb, Susan L. Knoxa, Rebecca F. Wissnera, Samuel Berryc, and Alanna Schepartza,b,1 aDepartment of Chemistry, Yale University, New Haven, CT 06520-8107; bDepartment of Molecular, Cellular and Developmental Biology, Yale University, New Haven, CT 06520-8103; and cDepartment of Molecular Biophysics and Biochemistry, Yale University, New Haven, CT 06520-8114 Edited by James A. Wells, University of California, San Francisco, CA, and approved November 26, 2018 (received for review July 17, 2018) Protein therapeutics represent a significant and growing compo- Recently, we discovered that, when added to cells, certain small, nent of the modern pharmacopeia, but their potential to treat folded miniature proteins (9, 10) derived from avian pancreatic human disease is limited because most proteins fail to traffic polypeptide (aPP) or an isolated zinc-finger (ZF) domain, are across biological membranes. Recently, we discovered a class of taken up into the endocytic pathway and subsequently released cell-permeant miniature proteins (CPMPs) containing a precisely into the cytosol with unprecedented efficiencies (11, 12). The most defined, penta-arginine (penta-Arg) motif that traffics readily to effective molecules are defined by a discrete array of five arginine the cytosol and nucleus of mammalian cells with efficiencies that residues on a folded α-helix (13); we refer to these molecules as rival those of hydrocarbon-stapled peptides active in animals and cell-permeant miniature proteins (CPMPs). Treatment of HeLa man. Like many cell-penetrating peptides (CPPs), CPMPs enter the cells in culture with the CPMP ZF5.3 leads to a ZF5.3 concen- endocytic pathway; the difference is that CPMPs containing a penta- tration in the cytosol that is roughly 67% of the extracellular in- Arg motif are released efficiently from endosomes, while other CPPs cubation concentration; this value is at least 10-fold higher than are not.
    [Show full text]
  • Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib
    Supplementary Online Content Chen G, McQuade JL, Panka DJ, et al. Clinical, molecular and immune analysis of dabrafenib-trametinib combination treatment for metastatic melanoma that progressed during BRAF inhibitor monotherapy: a phase 2 clinical trial. JAMA Oncology. Published online April 28, 2016. doi:10.1001/jamaoncol.2016.0509. eMethods. eReferences. eTable 1. Clinical efficacy eTable 2. Adverse events eTable 3. Correlation of baseline patient characteristics with treatment outcomes eTable 4. Patient responses and baseline IHC results eFigure 1. Kaplan-Meier analysis of overall survival eFigure 2. Correlation between IHC and RNAseq results eFigure 3. pPRAS40 expression and PFS eFigure 4. Baseline and treatment-induced changes in immune infiltrates eFigure 5. PD-L1 expression eTable 5. Nonsynonymous mutations detected by WES in baseline tumors This supplementary material has been provided by the authors to give readers additional information about their work. © 2016 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/30/2021 eMethods Whole exome sequencing Whole exome capture libraries for both tumor and normal samples were constructed using 100ng genomic DNA input and following the protocol as described by Fisher et al.,3 with the following adapter modification: Illumina paired end adapters were replaced with palindromic forked adapters with unique 8 base index sequences embedded within the adapter. In-solution hybrid selection was performed using the Illumina Rapid Capture Exome enrichment kit with 38Mb target territory (29Mb baited). The targeted region includes 98.3% of the intervals in the Refseq exome database. Dual-indexed libraries were pooled into groups of up to 96 samples prior to hybridization.
    [Show full text]
  • The Hypothalamus As a Hub for SARS-Cov-2 Brain Infection and Pathogenesis
    bioRxiv preprint doi: https://doi.org/10.1101/2020.06.08.139329; this version posted June 19, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. The hypothalamus as a hub for SARS-CoV-2 brain infection and pathogenesis Sreekala Nampoothiri1,2#, Florent Sauve1,2#, Gaëtan Ternier1,2ƒ, Daniela Fernandois1,2 ƒ, Caio Coelho1,2, Monica ImBernon1,2, Eleonora Deligia1,2, Romain PerBet1, Vincent Florent1,2,3, Marc Baroncini1,2, Florence Pasquier1,4, François Trottein5, Claude-Alain Maurage1,2, Virginie Mattot1,2‡, Paolo GiacoBini1,2‡, S. Rasika1,2‡*, Vincent Prevot1,2‡* 1 Univ. Lille, Inserm, CHU Lille, Lille Neuroscience & Cognition, DistAlz, UMR-S 1172, Lille, France 2 LaBoratorY of Development and PlasticitY of the Neuroendocrine Brain, FHU 1000 daYs for health, EGID, School of Medicine, Lille, France 3 Nutrition, Arras General Hospital, Arras, France 4 Centre mémoire ressources et recherche, CHU Lille, LiCEND, Lille, France 5 Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Center for Infection and ImmunitY of Lille (CIIL), Lille, France. # and ƒ These authors contriButed equallY to this work. ‡ These authors directed this work *Correspondence to: [email protected] and [email protected] Short title: Covid-19: the hypothalamic hypothesis 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.06.08.139329; this version posted June 19, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • Supplementary Figures
    Supplementary Figures Fig. S1. Distribution of total mutation pool. a) Statistics of different mutational types. b) The distribution of mutational allele frequency. c) Circle graph illustrating the chromosomal assignment of total mutation pool. The outer ring provides an overview of detected ctDNA mutations in each chromosome, while the inner ring shows the mutation burden of each chromosome. 1 Fig. S2. DNMT3A mutations in the experimental cohort. The upper graph shows all 19 DNMT3A mutations and their protein localization. The red rectangle indicates DNA_methylase domains. The lollipop graph is generated by online tools of cbioportal (http://www.cbioportal.org/visualize). The lower graph illustrates the diagnostic age distribution for patients with and without DNMT3A mutations. The p value is calculated by nonparametric t-test. 2 Fig. S3. Overview of clinical actionability for patients with drug-sensitive and resistant mutations. Each horizontal column represents an individual patients. Columns with different colors indicate diverse actionable mutations, and the length of column represents the number of mutations. Patients are divided into three groups using horizontal dotted lines, according to the mutation types. 3 Fig. S4. Concordance and mutant allele frequencies for matched sample pairs. Venn diagrams present the mutation overlap between matched tissue and blood samples. Scatter diagrams show the correlation between the allele frequencies of overlapping mutations in ctDNA vs. tissue DNA. Each dot represents an overlapping mutation,
    [Show full text]
  • Genome‑Wide Copy Number Analysis of Circulating Tumor Cells in Breast Cancer Patients with Liver Metastasis
    ONCOLOGY REPORTS 44: 1075-1093, 2020 Genome‑wide copy number analysis of circulating tumor cells in breast cancer patients with liver metastasis LINGLIN ZOU1*, SABER IMANI1*, MAZAHER MAGHSOUDLOO2,3, MARZIEH DEHGHAN SHASALTANEH4, LANYANG GAO5, JIA ZHOU6, QINGLIAN WEN1, SHUYA LIU1, LEISHENG ZHANG7 and GANG CHEN8 1Department of Oncology, The Affiliated Hospital of Southwest Medical University, Southwest Medical University, Luzhou, Sichuan 646000, P.R. China; 2Laboratory of Systems Biology and Bioinformatics (LBB), Institute of Biochemistry and Biophysics, University of Tehran, Tehran 1417614411; 3Department of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran 1916893813; 4Department of Biology, Faculty of Science, University of Zanjan, Zanjan 4537138791, Iran; 5Sichuan Provincial Center for Gynaecology and Breast Disease, The Affiliated Hospital of Southwest Medical University;6 School of Humanities and Management Science, Southwest Medical University, Luzhou, Sichuan 646000; 7The Postdoctoral Research Station, School of Medicine, Nankai University, Tianjin 300071; 8Department of Medical Equipment, The Affiliated Hospital of Southwest Medical University, Southwest Medical University, Luzhou, Sichuan 646000, P.R. China Received December 6, 2019; Accepted May 12, 2020 DOI: 10.3892/or.2020.7650 Abstract. The genome-wide copy number analysis of circu- lating tumor cells (CTCs) provides a promising prognostic biomarker for survival in breast cancer liver metastasis Correspondence to:
    [Show full text]
  • Explorations in Olfactory Receptor Structure and Function by Jianghai
    Explorations in Olfactory Receptor Structure and Function by Jianghai Ho Department of Neurobiology Duke University Date:_______________________ Approved: ___________________________ Hiroaki Matsunami, Supervisor ___________________________ Jorg Grandl, Chair ___________________________ Marc Caron ___________________________ Sid Simon ___________________________ [Committee Member Name] Dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Department of Neurobiology in the Graduate School of Duke University 2014 ABSTRACT Explorations in Olfactory Receptor Structure and Function by Jianghai Ho Department of Neurobiology Duke University Date:_______________________ Approved: ___________________________ Hiroaki Matsunami, Supervisor ___________________________ Jorg Grandl, Chair ___________________________ Marc Caron ___________________________ Sid Simon ___________________________ [Committee Member Name] An abstract of a dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Department of Neurobiology in the Graduate School of Duke University 2014 Copyright by Jianghai Ho 2014 Abstract Olfaction is one of the most primitive of our senses, and the olfactory receptors that mediate this very important chemical sense comprise the largest family of genes in the mammalian genome. It is therefore surprising that we understand so little of how olfactory receptors work. In particular we have a poor idea of what chemicals are detected by most of the olfactory receptors in the genome, and for those receptors which we have paired with ligands, we know relatively little about how the structure of these ligands can either activate or inhibit the activation of these receptors. Furthermore the large repertoire of olfactory receptors, which belong to the G protein coupled receptor (GPCR) superfamily, can serve as a model to contribute to our broader understanding of GPCR-ligand binding, especially since GPCRs are important pharmaceutical targets.
    [Show full text]
  • Investigating the Effects of Copy Number Variants on Reading and Language Performance Alessandro Gialluisi1,2, Alessia Visconti3, Erik G
    Gialluisi et al. Journal of Neurodevelopmental Disorders (2016) 8:17 DOI 10.1186/s11689-016-9147-8 RESEARCH Open Access Investigating the effects of copy number variants on reading and language performance Alessandro Gialluisi1,2, Alessia Visconti3, Erik G. Willcutt4,5, Shelley D. Smith6, Bruce F. Pennington7, Mario Falchi3, John C. DeFries4,5, Richard K. Olson4,5, Clyde Francks1,8* and Simon E. Fisher1,8* Abstract Background: Reading and language skills have overlapping genetic bases, most of which are still unknown. Part of the missing heritability may be caused by copy number variants (CNVs). Methods: In a dataset of children recruited for a history of reading disability (RD, also known as dyslexia) or attention deficit hyperactivity disorder (ADHD) and their siblings, we investigated the effects of CNVs on reading and language performance. First, we called CNVs with PennCNV using signal intensity data from Illumina OmniExpress arrays (~723,000 probes). Then, we computed the correlation between measures of CNV genomic burden and the first principal component (PC) score derived from several continuous reading and language traits, both before and after adjustment for performance IQ. Finally, we screened the genome, probe-by-probe, for association with the PC scores, through two complementary analyses: we tested a binary CNV state assigned for the location of each probe (i.e., CNV+ or CNV−), and we analyzed continuous probe intensity data using FamCNV. Results: No significant correlation was found between measures of CNV burden and PC scores, and no genome-wide significant associations were detected in probe-by-probe screening. Nominally significant associations were detected (p~10−2–10−3)withinCNTN4 (contactin 4) and CTNNA3 (catenin alpha 3).
    [Show full text]
  • A Point of Rarity in Genetic Risk for Bipolar Disorder and Schizophrenia
    WEB-ONLY CONTENT Rare Copy Number Variants A Point of Rarity in Genetic Risk for Bipolar Disorder and Schizophrenia Detelina Grozeva, MSc; George Kirov, PhD, MRCPsych; Dobril Ivanov, MSc; Ian R. Jones, PhD, MRCPsych; Lisa Jones, PhD; Elaine K. Green, PhD; David M. St Clair, MD, PhD; Allan H. Young, PhD, FRCPsych; Nicol Ferrier, PhD, FRCPsych; Anne E. Farmer, PhD, FRCPsych; Peter McGuffin, PhD, FRCPsych; Peter A. Holmans, PhD*; Michael J. Owen, PhD, FRCPsych*; Michael C. O’Donovan, PhD, FRCPsych*; Nick Craddock, PhD, FRCPsych*; for the Wellcome Trust Case Control Consortium Arch Gen Psychiatry. 2010;67(4):318-327 14 RESULTS schizophrenia article. In cases, this is caused by the ex- clusion of schizoaffective cases in the current analysis. The differences with regard to controls are caused by re- COMPARISON OF BURDEN OF COPY NUMBER analysis of a small subset of them. Some of the control VARIANTS ACCORDING TO SIZE BETWEEN data were processed with the use of different reference BIPOLAR CASES, CONTROLS, AND batches, which enabled us to include more controls in SCHIZOPHRENIA CASES the current analysis. We compared our bipolar disorder cases against our set of schizophrenia cases from the same population who had CNVs THAT OCCURRED MORE OFTEN IN been examined by the same methods (n=440).14 The copy BIPOLAR DISORDER CASES THAN CONTROLS number variants (CNVs) were classified into size cat- egories as in our previous report. eTable 1 shows the Although we did not observe an overall increase of CNV results. Compared with bipolar disorder, in the schizo- burden in bipolar cases compared with controls, some phrenia sample we observed a significant excess of large individual CNVs were more common in cases than con- deletions (PϽ.001) and total large CNVs (PϽ.001) and trols.
    [Show full text]
  • Supplementary Methods
    doi: 10.1038/nature06162 SUPPLEMENTARY INFORMATION Supplementary Methods Cloning of human odorant receptors 423 human odorant receptors were cloned with sequence information from The Olfactory Receptor Database (http://senselab.med.yale.edu/senselab/ORDB/default.asp). Of these, 335 were predicted to encode functional receptors, 45 were predicted to encode pseudogenes, 29 were putative variant pairs of the same genes, and 14 were duplicates. We adopted the nomenclature proposed by Doron Lancet 1. OR7D4 and the six intact odorant receptor genes in the OR7D4 gene cluster (OR1M1, OR7G2, OR7G1, OR7G3, OR7D2, and OR7E24) were used for functional analyses. SNPs in these odorant receptors were identified from the NCBI dbSNP database (http://www.ncbi.nlm.nih.gov/projects/SNP) or through genotyping. OR7D4 single nucleotide variants were generated by cloning the reference sequence from a subject or by inducing polymorphic SNPs by site-directed mutagenesis using overlap extension PCR. Single nucleotide and frameshift variants for the six intact odorant receptors in the same gene cluster as OR7D4 were generated by cloning the respective genes from the genomic DNA of each subject. The chimpanzee OR7D4 orthologue was amplified from chimpanzee genomic DNA (Coriell Cell Repositories). Odorant receptors that contain the first 20 amino acids of human rhodopsin tag 2 in pCI (Promega) were expressed in the Hana3A cell line along with a short form of mRTP1 called RTP1S, (M37 to the C-terminal end), which enhances functional expression of the odorant receptors 3. For experiments with untagged odorant receptors, OR7D4 RT and S84N variants without the Rho tag were cloned into pCI.
    [Show full text]